Akebia Ther (AKBA)

Akebia Ther (AKBA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $171M; returns 1 day +0.8%, 1 week -15.4%, 1 year -81.0%.

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for kidney disease. As of January 2026, Akebia's primary revenue driver is Vafseo (vadadustat), an oral therapy approved for anemia due to chronic kidney disease (CKD) in adults receiving dialysis.

Groups AKBA belongs to

• Healthcare
• Biotechnology
• Pharmaceuticals
• Nephrology
• Biopharmaceutical
• Commercial Stage
• Commercial Stage Biotech
• Chronic Disease Management
• Rare Diseases

AKBA financial model: income statement, cash flow and balance sheet